Throughout the cold chain there is a fundamental shift underway in the areas of responsibility and risk aversion. These changes are being spurred on due to cost cutting by the large biotech and pharmaceutical companies and the changing FDA recommendations and mandates related to biopharmaceutical and ambient temperature products.
This article by industry consultant Peter Norton discusses the impacts of these shifts on the three tiers of the supply chain and the importance of cold chain monitoring.
Please fill out the form to receive a copy of the article.